Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude comparant Zanubrutinib + Rituximab versus Bendamustine + Rituximab chez des participants atteints de lymphome à cellules du manteau non traité (MANGROVE)

25 septembre 2026 mis à jour par: BeOne Medicines

Une étude de phase 3 randomisée, ouverte et multicentrique comparant le zanubrutinib (BGB-3111) plus le rituximab à la bendamustine plus le rituximab chez des patients atteints d'un lymphome à cellules du manteau non préalablement traité qui ne sont pas éligibles à une greffe de cellules souches

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Aperçu de l'étude

Description détaillée

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Type d'étude

Interventionnel

Inscription (Réel)

510

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Cologne, Allemagne, 50937
        • Uniklinik Koln (Aor)
      • Heidelberg, Allemagne, 69120
        • Universitatsklinikum Heidelberg
      • Munich, Allemagne, 81377
        • Dept of Medicine Iii, University Hospitallmu
      • Ulm, Allemagne, 89081
        • Universitaetsklinikum Ulm, Innere Medizin Iii
      • Wuppertal, Allemagne, 42283
        • Petrus Krankenhaus Wuppertal
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australie, 2605
        • Canberra Hospital
    • New South Wales
      • Concord, New South Wales, Australie, 2139
        • Concord Repatriation General Hospital
      • Cudgen, New South Wales, Australie, 2487
        • The Tweed Valley Hospital
      • Darlinghurst, New South Wales, Australie, 2010
        • Saint Vincents Hospital Sydney
      • Gosford, New South Wales, Australie, 2250
        • Gosford Hospital
      • Waratah, New South Wales, Australie, 2298
        • Calvary Mater Newcastle
    • Queensland
      • Birtinya, Queensland, Australie, 4575
        • Sunshine Coast Hospital and Health Service
      • South Brisbane, Queensland, Australie, 4101
        • Icon Cancer Foundation
    • South Australia
      • Bedford PK, South Australia, Australie, 5042
        • Flinders Medical Centre
    • Tasmania
      • Hobart, Tasmania, Australie, 7000
        • Royal Hobart Hospital
    • Victoria
      • Clayton, Victoria, Australie, 3168
        • Monash Health
      • Fitzroy, Victoria, Australie, 3065
        • St Vincents Hospital Melbourne
      • Frankston, Victoria, Australie, 3199
        • Peninsula Private Hospital
      • Geelong, Victoria, Australie, 3220
        • Barwon Health the Geelong Hospital
    • Western Australia
      • Perth, Western Australia, Australie, 6000
        • Royal Perth Hospital
      • Bruges, Belgique, 8000
        • Az Sint Jan Brugge
      • Brussels, Belgique, 1090
        • Universitair Ziekenhuis Brussel
      • Edegem, Belgique, 2650
        • Uz Antwerpen
      • Kortrijk, Belgique, 8500
        • Az Groeninge Campus Loofstraat
      • Liège, Belgique, 4000
        • Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman
      • Yvoir, Belgique, 5530
        • Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8M2
        • The Ottawa Hospital
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Ciusss de Lestrie Chus
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100044
        • Peking University Peoples Hospital
      • Beijing, Beijing Municipality, Chine, 100050
        • Beijing Friendship Hospital, Capital Medical University
    • Fujian
      • Fuzhou, Fujian, Chine, 350001
        • Fujian Medical University Union Hospital
      • Quanzhou, Fujian, Chine, 362000
        • Quanzhou First Affliated Hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510080
        • Guangdong Provincial Peoples Hospital
      • Guangzhou, Guangdong, Chine, 510515
        • Nanfang Hospital of Southern Medical University
      • Guangzhou, Guangdong, Chine, 510060
        • Sun Yat Sen University Cancer Center
    • Heilongjiang
      • Harbin, Heilongjiang, Chine, 150000
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou, Henan, Chine, 450000
        • Henan Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Chine, 430030
        • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, Chine, 410013
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210029
        • Jiangsu Province Hospital
      • Nanjing, Jiangsu, Chine, 210008
        • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
      • Xuzhou, Jiangsu, Chine, 221000
        • The Affiliated Hospital of Xuzhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330006
        • The First Affiliated Hospital of Nanchang University Branch Donghu
    • Jilin
      • Changchun, Jilin, Chine, 130021
        • The First Hospital of Jilin University
      • Changchun, Jilin, Chine, 130021
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, Chine, 110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 200000
        • Fudan University Shanghai Cancer Center
      • Shanghai, Shanghai Municipality, Chine, 200120
        • Shanghai East Hospital
    • Sichuan
      • Chengdu, Sichuan, Chine, 610041
        • West China Hospital, Sichuan University
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chine, 300060
        • Tianjin Medical University Cancer Institute and Hospital
      • Tianjin, Tianjin Municipality, Chine, 300020
        • Institute of Hematology and Hospital of Blood Disease
    • Xinjiang
      • Ürümqi, Xinjiang, Chine, 830000
        • Affiliated Cancer Hospital of Xinjiang Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, Chine, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, Chine, 310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
      • Ningbo, Zhejiang, Chine, 315000
        • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
      • Barcelona, Espagne, 08035
        • Hospital Universitario Vall Dhebron
      • Barcelona, Espagne, 08916
        • Ico Hug Trias I Pujol
      • Barcelona, Espagne, 08908
        • Institut Catala Doncologia
      • Girona, Espagne, 17007
        • Ico Girona
      • Madrid, Espagne, 28046
        • Hospital Universitario La Paz
      • Madrid, Espagne, 28040
        • Start Madrid Fundacion Jimenez Diaz
      • Madrid, Espagne, 28033
        • Md Anderson Cancer Center Madrid Spain
      • Madrid, Espagne, 28009
        • Hospital Universitario Gregorio Maranon
      • Málaga, Espagne, 29010
        • Hospital Regional Universitario de Malaga
      • Seville, Espagne, 41013
        • Hospital Universitario Virgen Del Rocio
      • Bordeaux, France, 33076
        • Centre de Lutte Contre Le Cancer Institut Bergonie
      • Brest, France, 29200
        • Chru de Brest Hospital Morvan
      • Dijon, France, J4V 2H1
        • Chu Dijon
      • Grenoble, France, 38043
        • Chu Grenoble Alpes
      • Le Mans, France, 72037
        • Centre Hospitalier Le Mans
      • Lille, France, 59000
        • Hopital Claude Huriez Chu Lille
      • Marseille, France, 13009
        • Institut Paoli Calmettes
      • Nantes, France, 44093
        • Centre Hospitalier Universitaire Nantes Hotel Dieu
      • Paris, France, 75005
        • Institut Curie
      • Paris, France, 75015
        • Necker University Hospital
      • PierreBenite, France, 69495
        • Chu Hopital Lyon Sud
      • Poitiers, France, 86000
        • Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
      • Quimper, France, 29000
        • Ch Cornouaille
      • Toulouse, France, 31059
        • Iuc Toulouse Oncopole
      • Cork, Irlande, t12DC4A
        • Cork University Hospital
      • Dublin, Irlande, D7
        • Mater Misericordiae University Hospital
      • Dublin, Irlande, D8
        • St Jamess Hospital
      • Galway, Irlande, H91 YR71
        • University Hospital Galway
      • Limerick, Irlande, V94F858
        • University Hospital Limerick
      • Waterford, Irlande, X91 ER8E
        • University Hospital Waterford
      • Alessandria, Italie, 15121
        • Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo
      • Bologna, Italie, 40138
        • Policlinico Sorsola Malpighi, Aou Di Bologna
      • Genova, Italie, 16132
        • Azienda Ospedaliera Universitaria San Martino
      • Milan, Italie, 20162
        • Niguarda Cancer Center Division of Hematology
      • Novara, Italie, 28100
        • Aou Maggiore Della Carita
      • Palermo, Italie, 90146
        • Aoor Villa Sofia Cervello
      • Pisa, Italie, 56126
        • Aou Pisana, Stabilimento Di Santa Chiara
      • Ravenna, Italie, 48121
        • Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
      • Reggio Emilia, Italie, 42123
        • Azienda Unita Sanitaria Locale Irccs
      • Roma, Italie, 00161
        • Universita Degli Studi La Sapienza
      • Siena, Italie, 53100
        • Aou Senese Policlinico Santa Maria Alle Scotte
      • Torino, Italie, 10126
        • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
      • Verona, Italie, 37142
        • University of Verona
      • Yokohama, Japon, 221-0855
        • Yokohama Municipal Citizens Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 460-0001
        • National Hospital Organization Nagoya Medical Center
      • Toyohashi, Aichi-ken, Japon, 441-8570
        • Toyohashi Municipal Hospital
    • Chiba
      • Chiba, Chiba, Japon, 260-8717
        • Chiba Cancer Center
    • Fukuoka
      • Kurume, Fukuoka, Japon, 830-0011
        • Kurume University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, Japon, 730-8619
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japon, 241-8515
        • Kanagawa Cancer Center
    • Kumamoto
      • Kumamoto, Kumamoto, Japon, 860-0008
        • National Hospital Organization Kumamoto Medical Center
    • Kyoto
      • Kyoto, Kyoto, Japon, 602-8566
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai, Miyagi, Japon, 980-8574
        • Tohoku University Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, Japon, 710-8602
        • Kurashiki Central Hospital
      • Okayama, Okayama-ken, Japon, 701-1192
        • National Hospital Organization Okayama Medical Center
    • Osaka
      • Osaka, Osaka, Japon, 545-8586
        • Osaka Metropolitan University Hospital
      • Osakashi, Osaka, Japon, 543-8555
        • Osaka Red Cross Hospital
    • Tokyo
      • Chuoku, Tokyo, Japon, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Tokyo, Japon, 113-8519
        • Tokyo Medical and Dental University Hospital
      • Linz, L'Autriche, 4020
        • Ordensklinikum Linz Gmbh Elisabethinen
      • Salzburg, L'Autriche, 5020
        • Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
      • Vienna, L'Autriche, 1090
        • Medical University Vienna Oncology
      • Lisbon, Le Portugal, 1099-023
        • Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe
      • Lisbon, Le Portugal, 1649-035
        • Chuln Hospital de Santa Maria
      • Porto, Le Portugal, 4099-001
        • Centro Hospitalar Universitario Porto
      • Porto, Le Portugal, 4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe
      • Christchurch, Nouvelle-Zélande, 8011
        • Christchurch Hospital (Canterbury Health Laboratories)
      • Tauranga, Nouvelle-Zélande, 3112
        • Tauranga Hospital
      • Goes, Pays-Bas, 4462 RA
        • Admiraal de Ruijter Ziekenhuis
      • Groningen, Pays-Bas, 9713 GZ
        • University of Medical Center Groningen (Umcg)
      • Nieuwegein, Pays-Bas, 3435 CM
        • St Antonius Ziekenhuis, Randd Interne Geneeskunde (F)
      • Nijmegen, Pays-Bas, 6525 GA
        • Albert Schweitzer Ziekenhuis
      • Rotterdam, Pays-Bas, 3015 GD
        • Erasmus Mc
      • The Hague, Pays-Bas, 2545 CH
        • Hagaziekenhuis
      • Bydgoszcz, Pologne, 85-168
        • Szpital Uniwersytecki Nr Im Dr Jana Biziela
      • Chorzów, Pologne, 41-503
        • Silesian Healthy Blood Clinic
      • Gdansk, Pologne, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Gdask, Pologne, 80-219
        • Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
      • Gdynia, Pologne, 81-519
        • Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
      • Krakow, Pologne, 30-727
        • Pratia McM Krakow
      • Legnica, Pologne, 59-220
        • Wojewodzki Szpital Specjalistyczny W Legnicy
      • Lodz, Pologne, 93-510
        • Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, Pologne, 20-090
        • Centrum Onkologii Ziemi Lubelskiej
      • Warsaw, Pologne, 02-776
        • Instytut Hematologii I Transfuzjologii W Warszawie
      • Wałbrzych, Pologne, 58-309
        • Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego
      • Wroclaw, Pologne, 50-556
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
      • Bucharest, Roumanie, 022328
        • Institutul Clinic Fundeni
      • Iași, Roumanie, 700483
        • Institutul Regional de Oncologie Iasi
      • Abergavenny, Royaume-Uni, NP7 7EG
        • Aneurin Bevan University Health Board
      • Birmingham, Royaume-Uni, B9 5SS
        • Birmingham Heartlands Hospital
      • Dudley, Royaume-Uni, DY1 2HQ
        • Russells Hall Hopsital
      • Sutton, Royaume-Uni, SM2 5PT
        • Royal Marsden Nhs Foundation Royal Marsden Hospital
      • Moscow, Russie, 142770
        • Gbuz Mmcc Kommunarka Dzm
    • Moscow
      • Moscow, Moscow, Russie, 125284
        • Clinical Hospital, Sp Botkin
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Russie, 191024
        • Fgu Russian Scientific Research Institute of Hematology and Transfusiology
      • Saint Petersburg, Sankt-Peterburg, Russie, 194291
        • Leningrad Regional Clinic and Hospital
      • Tainan, Taïwan, 704
        • National Cheng Kung University Hospital
      • Tainan, Taïwan, 736
        • Chi Mei Hospital Liouying
      • Taipei, Taïwan, 114
        • Tri Service General Hospital
      • Ankara, Turquie (Türkiye), 06620
        • Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
      • Ankara, Turquie (Türkiye), 6500
        • Gazi University
      • Ankara, Turquie (Türkiye), 06700
        • Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi
      • Edirne, Turquie (Türkiye), 22030
        • Tr Trakya University Health Research and Application Center (Hospital)
      • Istanbul, Turquie (Türkiye), 34365
        • Vkv American Hospital
      • Mersin, Turquie (Türkiye), 33000
        • Mersin Universitesi Tip Fakultesi Hastanesi
      • Cherkasy, Ukraine, 18009
        • Cherkasy Regional Oncology Dispensary
      • Dnipro, Ukraine, 49102
        • Municipal Non Profit Enterprise City Clinical Hospital
      • Kiev, Ukraine, 3022
        • National Cancer Institute
      • Lviv, Ukraine, 79044
        • Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department
    • California
      • Orange, California, États-Unis, 92868
        • Chao Family Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, États-Unis, 60612
        • Rush University Medical Center
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215-5400
        • Beth Israel Deaconess Medical Center (Bidmc)
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • University of Michigan Health System
    • Nevada
      • Las Vegas, Nevada, États-Unis, 89169
        • Comprehensive Cancer Centers of Nevada
    • New York
      • New York, New York, États-Unis, 10029
        • Icahn School of Medicine At Mount Sinai
      • Westbury, New York, États-Unis, 11590
        • Clinical Research Alliance, Inc
    • Oregon
      • Portland, Oregon, États-Unis, 97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, États-Unis, 15224
        • West Penn Hospital
    • Texas
      • Houston, Texas, États-Unis, 77030-4009
        • The University of Texas Md Anderson Cancer Center
      • Lubbock, Texas, États-Unis, 79410
        • Joe Arrington Cancer Research and Treatment Center
    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Seattle Cancer Care Alliance

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  1. ≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
  2. Histologically confirmed diagnosis of MCL
  3. No prior systemic treatments for MCL
  4. Measurable disease by CT/MRI
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  6. Adequate marrow and organ function

Key Exclusion Criteria:

  1. Known central nervous system involvement by lymphoma
  2. Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
  3. Clinically significant cardiovascular disease
  4. History of severe bleeding disorder
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function
  6. Active fungal, bacterial and/or viral infection requiring systemic therapy
  7. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm A: zanubrutinib plus rituximab

Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression.

Administered as two 80 mg capsules by mouth twice a day

Autres noms:
  • Brukinsa
  • BGB-3111

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Comparateur actif: Arm B: bendamustine plus rituximab

Participants will receive bendamustine plus rituximab, followed by observation.

Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS) determined by independent central review
Délai: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
PFS by investigator assessment
Délai: Up to approximately 7 years

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.

Up to approximately 7 years
Overall response rate (ORR)
Délai: Up to approximately 7 years

ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment.

Up to approximately 7 years
Duration of response (DOR)
Délai: Up to approximately 7 years

DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first.

Up to approximately 7 years
Overall survival (OS)
Délai: Up to approximately 7 years

OS is defined as the time from randomization to the date of death due to any reason.

Up to approximately 7 years
Time to Response (TTR)
Délai: Up to approximately 7 years

TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response.

Up to approximately 7 years
Rate of complete response (CR) or complete metabolic response
Délai: Up to approximately 7 years

Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment.

Up to approximately 7 years
Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)
Délai: Up to approximately 7 years

EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health.

Up to approximately 7 years
PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Délai: Up to approximately 7 years

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).

Up to approximately 7 years
Number of participants with adverse events and serious adverse events
Délai: Up to approximately 7 years

Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings.

Up to approximately 7 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Study Director, BeOne Medicines

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 août 2019

Achèvement primaire (Réel)

27 avril 2026

Achèvement de l'étude (Estimé)

30 septembre 2031

Dates d'inscription aux études

Première soumission

27 juin 2019

Première soumission répondant aux critères de contrôle qualité

27 juin 2019

Première publication (Réel)

28 juin 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

25 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Délai de partage IPD

See plan description

Critères d'accès au partage IPD

See plan description

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner